Rheumatoid arthritis-associated interstitial lung disease

Open Access Rheumatology: Research and Reviews

Volumn 4, Issue , 2012, Pages 21-31

  Solomon, Joshua J ^a   Brown, Kevin K ^a  

^a DEPARTMENT OF MEDICINE   (United States)

Author keywords

Anti CCP; Interstitial lung disease; Nonspecific interstitial pneumonia; Rheumatoid arthritis; Usual interstitial pneumonia

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; BUCILLAMINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOSPORIN; GAMMA INTERFERON; GOLD; HLA DR ANTIGEN; INFLIXIMAB; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR ANTIBODY;

AGE DISTRIBUTION; ANTIBODY TITER; CLINICAL FEATURE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG USE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG DISEASE; LUNG FUNCTION TEST; LUNG LAVAGE; PATHOGENESIS; PREVALENCE; PROGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SMOKING; SURVIVAL RATE; THORAX RADIOGRAPHY;

EID: 84859074922     PISSN: None     EISSN: 1179156X     Source Type: Journal    
DOI: 10.2147/OARRR.S14723     Document Type: Review

References (134)

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376(9746):1094-1108.
2. van der Woude D, Houwing-Duistermaat JJ, Toes RE, et al. Quantitative heritability of anti-citrullinated protein antibody-positive and anticitrullinated protein antibody-negative rheumatoid arthritis. Arthritis Rheum. 2009;60(4):916-923.
3. Carlens C, Hergens MP, Grunewald J, et al. Smoking, use of moist snuff, and risk of chronic inflammatory diseases. Am J Respir Crit Care Med. 2010;181(11):1217-1222.
4. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2006;65(7): 845-851.
5. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004;50(2): 380-386.
6. Radovits BJ, Fransen J, Al Shamma S, Eijsbouts AM, van Riel PL, Laan RF. Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis. Arthritis Care Res (Hoboken). 2010;62(3):362-370.
7. Gabriel SE, Crowson CS, Kremers HM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum. 2003;48(1):54-58.
8. Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol. 2002;29(1):62-67.
9. Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis. 2003;62(8):722-727.
10. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005;52(3):722-732.
11. Koota K, Isomaki H, Mutru O. Death rate and causes of death in RA patients during a period of five years. Scand J Rheumatol. 1977;6(4):241-244.
12. Toyoshima H, Kusaba T, Yamaguchi M. Cause of death in autopsied RA patients. Ryumachi. 1993;33(3):209-214.
13. Minaur NJ, Jacoby RK, Cosh JA, Taylor G, Rasker JJ. Outcome after 40 years with rheumatoid arthritis: a prospective study of function, disease activity, and mortality. J Rheumatol Suppl. 2004;69:3-8.
14. Sihvonen S, Korpela M, Laippala P, Mustonen J, Pasternack A. Death rates and causes of death in patients with rheumatoid arthritis: a population-based study. Scand J Rheumatol. 2004;33(4):221-227.
15. Suzuki A, Ohosone Y, Obana M, et al. Cause of death in 81 autopsied patients with rheumatoid arthritis. J Rheumatol. 1994;21(1):33-36.
16. Young A, Koduri G, Batley M, et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology. 2007;46(2):350-357.
17. Tsuchiya Y, Takayanagi N, Sugiura H, et al. Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Euro Respir J. 2011;37(6):1411-1417.
18. Myasoedova E, Davis JM 3rd, Crowson CS, Gabriel SE. Epidemiology of rheumatoid arthritis: rheumatoid arthritis and mortality. Curr Rheumatol Rep. 2010;12(5):379-385.
19. Brown KK. Rheumatoid lung disease. Proc Am Thorac Soc. 2007; 4(5): 443-448.
20. Pappas DA, Giles JT, Connors G, Lechtzin N, Bathon JM, Danoff SK. Respiratory symptoms and disease characteristics as predictors of pulmonary function abnormalities in patients with rheumatoid arthritis: an observational cohort study. Arthritis Res Ther. 2010;12(3):R104.
21. Kanat F, Levendoglu F, Teke T. Radiological and functional assessment of pulmonary involvement in the rheumatoid arthritis patients. Rheumatol Int. 2007;27(5):459-466.
22. Bilgici A, Ulusoy H, Kuru O, Celenk C, Unsal M, Danaci M. Pulmonary involvement in rheumatoid arthritis. Rheumatol Int. 2005;25(6):429-435.
23. Fuld JP, Johnson MK, Cotton MM, et al. A longitudinal study of lung function in non-smoking patients with rheumatoid arthritis. Chest. 2003;124(4):1224-1231.
24. Avnon LS, Manzur F, Bolotin A, et al. Pulmonary functions testing in patients with rheumatoid arthritis. Isr Med Assoc J. 2009;11(2): 83-87.
25. Cortet B, Perez T, Roux N, et al. Pulmonary function tests and high resolution computed tomography of the lungs in patients with rheumatoid arthritis. Ann Rheum Dis. 1997;56(10):596-600.
26. Zrour SH, Touzi M, Bejia I, et al. Correlations between high-resolution computed tomography of the chest and clinical function in patients with rheumatoid arthritis. Prospective study in 75 patients. Joint Bone Spine. 2005;72(1):41-47.
27. Demir R, Bodur H, Tokoglu F, Olcay I, Ucan H, Borman P. High resolution computed tomography of the lungs in patients with rheumatoid arthritis. Rheumatol Int. 1999;19(1-2):19-22.
28. Hassan WU, Keaney NP, Holland CD, Kelly CA. High resolution computed tomography of the lung in lifelong non-smoking patients with rheumatoid arthritis. Ann Rheum Dis. 1995;54(4):308-310.
29. Perez T, Remy-Jardin M, Cortet B. Airways involvement in rheumatoid arthritis: clinical, functional, and HRCT findings. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1658-1665.
30. Terasaki H, Fujimoto K, Hayabuchi N, Ogoh Y, Fukuda T, Muller NL. Respiratory symptoms in rheumatoid arthritis: relation between high resolution CT findings and functional impairment. Radiat Med. 2004;22(3):179-185.
31. Metafratzi ZM, Georgiadis AN, Ioannidou CV, et al. Pulmonary involvement in patients with early rheumatoid arthritis. Scand J Rheumatol. 2007;36(5):338-344.
32. Garcia JG, Parhami N, Killam D, Garcia PL, Keogh BA. Bronchoalveolar lavage fluid evaluation in rheumatoid arthritis. Am Rev Respir Disease. 1986;133(3):450-454.
33. Gabbay E, Tarala R, Will R, et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med. 1997;156(2 Pt 1): 528-535.
34. Kolarz G, Scherak O, Popp W, et al. Bronchoalveolar lavage in rheumatoid arthritis. Br J Rheumatol. 1993;32(7):556-561.
35. Evans RB, Ettensohn DB, Fawaz-Estrup F, Lally EV, Kaplan SR. Gold lung: recent developments in pathogenesis, diagnosis, and therapy. Sem Arthritis Rheum. 1987;16(3):196-205.
36. Shettar SP, Chattopadhyay C, Wolstenholme RJ, Swinson DR. Diffuse alveolitis on a small dose of penicillamine. Br J Rheumatol. 1984;23(3):220-224.
37. Negishi M, Kaga S, Kasama T, et al. Lung injury associated with bucillamine therapy. Ryumachi. 1992;32(2):135-139. Japanese.
38. Inokuma S. Leflunomide-induced interstitial pneumonitis might be a representative of disease-modifying antirheumatic drug-induced lung injury. Expert Opin Drug Saf. 2011;10(4):603-611.
39. Kremer JM, Alarcon GS, Weinblatt ME, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum. 1997;40(10): 1829-1837.
40. Cannon GW. Methotrexate pulmonary toxicity. Rheum Dis Clin North Am. 1997;23(4):917-937.
41. Hamadeh MA, Atkinson J, Smith LJ. Sulfasalazine-induced pulmonary disease. Chest. 1992;101(4):1033-1037.
42. Chatterjee S. Severe interstitial pneumonitis associated with infliximab therapy. Scand J Rheumatol. 2004;33(4):276-277.
43. Ostor AJ, Chilvers ER, Somerville MF, et al. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. J Rheumatol. 2006;33(3):622-628.
44. Koike R, Tanaka M, Komano Y, et al. Tacrolimus-induced pulmonary injury in rheumatoid arthritis patients. Pulm Pharmacol Ther. 2011;24(4):401-406.
45. Miwa Y, Isozaki T, Wakabayashi K, et al. Tacrolimus-induced lung injury in a rheumatoid arthritis patient with interstitial pneumonitis. Mod Rheumatol. 2008;18(2):208-211.
46. Cottin V, Tebib J, Massonnet B, Souquet PJ, Bernard JP. Pulmonary function in patients receiving long-term low-dose methotrexate. Chest. 1996;109(4):933-938.
47. Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology. 2005;44(1):61-66.
48. Khadadah ME, Jayakrishnan B, Al-Gorair S, et al. Effect of methotrexate on pulmonary function in patients with rheumatoid arthritis - a prospective study. Rheumatol Int. 2002;22(5):204-207.
49. Dawson JK, Graham DR, Desmond J, Fewins HE, Lynch MP. Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology (Oxford). 2002;41(3):262-267.
50. Gaffo AL, Alarcon GS. Methotrexate is not associated with progression of interstitial lung disease in rheumatoid arthritis. Arch Intern Med. 2008;168(17):1927-1928.
51. Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med. 2008;168(2):159-166.
52. Courtney PA, Alderdice J, Whitehead EM. Comment on methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum. 2003;49(4):617; author reply 617-618.
53. Kramer N, Chuzhin Y, Kaufman LD, Ritter JM, Rosenstein ED. Methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum. 2002;47(6):670-671.
54. Gottenberg JE, Ravaud P, Bardin T, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum. 2010;62(9):2625-2632.
55. Hernandez-Cruz B, Garcia-Arias M, Ariza Ariza R, Martin Mola E. Rituximab in rheumatoid arthritis: a systematic review of efficacy and safety. Reumatol Clin. 2011;7(5):314-322. Spanish.
56. Ellman P, Ball RE. Rheumatoid disease with joint and pulmonary manifestations. Br Med J. 1948;2(4583):816-820.
57. Cudkowicz L, Madoff IM, Abelmann WH. Rheumatoid lung disease. A case report which includes respiratory function studies and a lung biopsy. Br J Dis Chest. 1961;55:35-40.
58. Aronoff A, Bywaters EG, Fearnley GR. Lung lesions in rheumatoid arthritis. Br Med J. 1955;2(4933):228-232.
59. Talbott JA, Calkins E. Pulmonary involvement in rheumatoid arthritis. JAMA. 1964;189:911-913.
60. Frank ST, Weg JG, Harkleroad LE, Fitch RF. Pulmonary dysfunction in rheumatoid disease. Chest. 1973;63(1):27-34.
61. Popper MS, Bogdonoff ML, Hughes RL. Interstitial rheumatoid lung disease. A reassessment and review of the literature. Chest. 1972;62(3): 243-250.
62. Popp W, Rauscher H, Ritschka L, et al. Prediction of interstitial lung involvement in rheumatoid arthritis. The value of clinical data, chest roentgenogram, lung function, and serologic parameters. Chest. 1992;102(2):391-394.
63. Cervantes-Perez P, Toro-Perez AH, Rodriguez-Jurado P. Pulmonary involvement in rheumatoid arthritis. JAMA. 1980;243(17): 1715-1719.
64. Fujii M, Adachi S, Shimizu T, Hirota S, Sako M, Kono M. Interstitial lung disease in rheumatoid arthritis: assessment with high-resolution computed tomography. J Thorac Imaging. 1993;8(1):54-62.
65. Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax. 2001;56(8):622-627.
66. Rajasekaran BA, Shovlin D, Lord P, Kelly CA. Interstitial lung disease in patients with rheumatoid arthritis: a comparison with cryptogenic fibrosing alveolitis. Rheumatology (Oxford). 2001;40(9): 1022-1025.
67. Horton MR. Rheumatoid arthritis associated interstitial lung disease. Crit Rev Comput Tomogr. 2004;45(5-6):429-440.
68. Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62(6):1583-1591.
69. Jurik AG, Davidsen D, Graudal H. Prevalence of pulmonary involvement in rheumatoid arthritis and its relationship to some characteristics of the patients. A radiological and clinical study. Scand J Rheumatol. 1982;11(4):217-224.
70. Saag KG, Kolluri S, Koehnke RK, et al. Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. Arthritis Rheum. 1996;39(10):1711-1719.
71. Banks J, Banks C, Cheong B, et al. An epidemiological and clinical investigation of pulmonary function and respiratory symptoms in patients with rheumatoid arthritis. Q J Med. 1992;85(307-308):795-806.
72. Aubart F, Crestani B, Nicaise-Roland P, et al. High levels of anti-cyclic citrullinated peptide autoantibodies are associated with co-occurrence of pulmonary diseases with rheumatoid arthritis. J Rheumatol. 2011;38(6):979-982.
73. Anaya JM, Diethelm L, Ortiz LA, et al. Pulmonary involvement in rheumatoid arthritis. Semin Arthritis Rheum. 1995;24(4): 242-254.
74. Shidara K, Hoshi D, Inoue E, et al. Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA. Mod Rheumatol. 2010;20(3):280-286.
75. Tanaka N, Kim JS, Newell JD, et al. Rheumatoid arthritis-related lung diseases: CT findings. Radiology. 2004;232(1):81-91.
76. Sakaida H. IgG rheumatoid factor in rheumatoid arthritis with interstitial lung disease. Ryumachi. 1995;35(4):671-677. Japanese.
77. Alexiou I, Germenis A, Koutroumpas A, Kontogianni A, Theodoridou K, Sakkas LI. Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis. Clin Rheumatol. 2008;27(4):511-513.
78. Scott TE, Wise RA, Hochberg MC, Wigley FM. HLA-DR4 and pulmonary dysfunction in rheumatoid arthritis. Am J Med. 1987;82(4):765-771.
79. Charles PJ, Sweatman MC, Markwick JR, Maini RN. HLA-B40: a marker for susceptibility to lung disease in rheumatoid arthritis. Dis Markers. 1991;9(2):97-101.
80. Tanoue LT. Pulmonary manifestations of rheumatoid arthritis. Clin Chest Med. 1998;19(4):667-685, viii.
81. Hyland RH, Gordon DA, Broder I, et al. A systematic controlled study of pulmonary abnormalities in rheumatoid arthritis. J Rheumatol. 1983;10(3):395-405.
82. Sugiyama Y, Ohno S, Kano S, Maeda H, Kitamura S. Diffuse panbronchiolitis and rheumatoid arthritis: a possible correlation with HLA-B54. Intern Med. 1994;33(10):612-614.
83. Hillarby MC, McMahon MJ, Grennan DM, et al. HLA associations in subjects with rheumatoid arthritis and bronchiectasis but not with other pulmonary complications of rheumatoid disease. Br J Rheumatol. 1993;32(9):794-797.
84. Michalski JP, McCombs CC, Scopelitis E, Biundo JJ Jr, Medsger TA Jr. Alpha 1-antitrypsin phenotypes, including M subtypes, in pulmonary disease associated with rheumatoid arthritis and systemic sclerosis. Arthritis Rheum. 1986;29(5):586-591.
85. Turesson C, Matteson EL, Colby TV, et al. Increased CD4+ T cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis. Arthritis Rheum. 2005;52(1):73-79.
86. Michel JJ, Turesson C, Lemster B, et al. CD56-expressing T cells that have features of senescence are expanded in rheumatoid arthritis. Arthritis Rheum. 2007;56(1):43-57.
87. Atkins SR, Turesson C, Myers JL, et al. Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia. Arthritis Rheum. 2006;54(2):635-641.
88. Song JW, Do KH, Kim MY, Jang SJ, Colby TV, Kim DS. Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia. Chest. 2009;136(1): 23-30.
89. Ancochea J, Giron RM, Lopez-Botet M. Production of tumor necrosis factor alpha and interleukin-6 by alveolar macrophages from patients with rheumatoid arthritis and interstitial pulmonary disease. Arch Bronconeumol. 1997;33(7):335-340. Spanish.
90. Horie S, Nakada K, Minota S, Kano S. High proliferative potential colony-forming cells (HPP-CFCs) in the peripheral blood of rheumatoid arthritis patients with interstitial lung disease. Scand J Rheumatol. 2003;32(5):273-276.
91. Albano SA, Santana-Sahagun E, Weisman MH. Cigarette smoking and rheumatoid arthritis. Sem Arthritis Rheum. 2001;31(3):146-159.
92. Jawaheer D, Gregersen PK. Rheumatoid arthritis. The genetic components. Rheum Dis Clin North Am. 2002;28(1):1-15, v.
93. Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54(1):38-46.
94. Makrygiannakis D, Hermansson M, Ulfgren AK, et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis. 2008;67(10):1488-1492.
95. De Rycke L, Nicholas AP, Cantaert T, et al. Synovial intracellular citrullinated proteins colocalizing with peptidyl arginine deiminase as pathophysiologically relevant antigenic determinants of rheumatoid arthritis-specific humoral autoimmunity. Arthritis Rheum. 2005;52(8):2323-2330.
96. Bongartz T, Cantaert T, Atkins SR, et al. Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatology (Oxford). 2007;46(1):70-75.
97. Stolt P, Bengtsson C, Nordmark B, et al. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis. 2003;62(9):835-841.
98. Ayhan-Ardic FF, Oken O, Yorgancioglu ZR, Ustun N, Gokharman FD. Pulmonary involvement in lifelong non-smoking patients with rheumatoid arthritis and ankylosing spondylitis without respiratory symptoms. Clin Rheumatol. 2006;25(2):213-218.
99. Biederer J, Schnabel A, Muhle C, Gross WL, Heller M, Reuter M. Correlation between HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease associated with rheumatoid arthritis. Eur Radiol. 2004;14(2):272-280.
100. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35(6):1322-1328.
101. Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest. 2005;127(6):2019-2027.
102. Luqmani R, Hennell S, Estrach C, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). Rheumatology. 2009;48(4):436-439.
103. Roschmann RA, Rothenberg RJ. Pulmonary fibrosis in rheumatoid arthritis: a review of clinical features and therapy. Semin Arthritis Rheum. 1987;16(3):174-185.
104. Rajasekaran A, Shovlin D, Saravanan V, Lord P, Kelly C. Interstitial lung disease in patients with rheumatoid arthritis: comparison with cryptogenic fibrosing alveolitis over 5 years. J Rheumatol. 2006;33(7):1250-1253.
105. Provenzano G. Asymptomatic pulmonary involvement in RA. Thorax. 2002;57(2):187-188.
106. Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR. Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis. Ann Rheum Dis. 2002;61(6):517-521.
107. Shannon TM, Gale ME. Noncardiac manifestations of rheumatoid arthritis in the thorax. J Thorac Imaging. 1992;7(2):19-29.
108. McDonagh J, Greaves M, Wright AR, Heycock C, Owen JP, Kelly C. High resolution computed tomography of the lungs in patients with rheumatoid arthritis and interstitial lung disease. Br J Rheumatol. 1994;33(2):118-122.
109. Akira M, Sakatani M, Hara H. Thin-section CT findings in rheumatoid arthritis-associated lung disease: CT patterns and their courses. J Comput Assist Tomogr. 1999;23(6):941-948.
110. Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest. 2009;136(5):1397-1405.
111. Okuda Y, Takasugi K, Kurata N, Takahara J. Bronchoalveolar lavage fluid analysis in rheumatoid arthritis. Ryumachi. 1993;33(4):302-309. Japanese.
112. Gilligan DM, O'Connor CM, Ward K, Moloney D, Bresnihan B, FitzGerald MX. Bronchoalveolar lavage in patients with mild and severe rheumatoid lung disease. Thorax. 1990;45(8):591-596.
113. Tishler M, Grief J, Fireman E, Yaron M, Topilsky M. Bronchoalveolar lavage - a sensitive tool for early diagnosis of pulmonary involvement in rheumatoid arthritis. J Rheumatol. 1986;13(3):547-550.
114. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med. 2007;175(7):705-711.
115. Devouassoux G, Cottin V, Liote H, et al. Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis. Eur Respir J. 2009;33(5):1053-1061.
116. Rangel-Moreno J, Hartson L, Navarro C, Gaxiola M, Selman M, Randall TD. Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest. 2006;116(12):3183-3194.
117. Yousem SA, Colby TV, Carrington CB. Lung biopsy in rheumatoid arthritis. Am Rev Respir Dis. 1985;131(5):770-777.
118. Kinoshita F, Hamano H, Harada H, et al. Role of KL-6 in evaluating the disease severity of rheumatoid lung disease: comparison with HRCT. Respir Med. 2004;98(11):1131-1137.
119. Scott DG, Bacon PA. Response to methotrexate in fibrosing alveolitis associated with connective tissue disease. Thorax. 1980;35(10): 725-731.
120. Cohen JM, Miller A, Spiera H. Interstitial pneumonitis complicating rheumatoid arthritis. Sustained remission with azathioprine therapy. Chest. 1977;72(4):521-524.
121. Chang HK, Park W, Ryu DS. Successful treatment of progressive rheumatoid interstitial lung disease with cyclosporine: a case report. J Korean Med Sci. 2002;17(2):270-273.
122. Saketkoo LA, Espinoza LR. Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and diseasemodifying antirheumatic drug. Arch Intern Med. 2008;168(15): 1718-1719.
123. Vassallo R, Matteson E, Thomas CF Jr. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. Chest. 2002;122(3):1093-1096.
124. Bargagli E, Galeazzi M, Rottoli P. Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis. Eur Respir J. 2004;24(4):708.
125. Ostor AJ, Crisp AJ, Somerville MF, Scott DG. Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. BMJ. 2004;329(7477):1266.
126. Villeneuve E, St-Pierre A, Haraoui B. Interstitial pneumonitis associated with infliximab therapy. J Rheumatol. 2006;33(6):1189-1193.
127. Peno-Green L, Lluberas G, Kingsley T, Brantley S. Lung injury linked to etanercept therapy. Chest. 2002;122(5):1858-1860.
128. Hagiwara K, Sato T, Takagi-Kobayashi S, Hasegawa S, Shigihara N, Akiyama O. Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis. J Rheumatol. 2007;34(5):1151-1154.
129. Dixon WG, Hyrich KL, Watson KD, Lunt M, Symmons DP. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2010;69(6):1086-1091.
130. Pratt DS, Schwartz MI, May JJ, Dreisin RB. Rapidly fatal pulmonary fibrosis: the accelerated variant of interstitial pneumonitis. Thorax. 1979;34(5):587-593.
131. Hakala M. Poor prognosis in patients with rheumatoid arthritis hospitalized for interstitial lung f ibrosis. Chest. 1988;93(1): 114-118.
132. Hubbard R, Venn A. The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis. Rheumatology (Oxford). 2002;41(6):676-679.
133. Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax. 1980;35(3):171-180.
134. Saravanan V, Kelly CA. Survival in fibrosing alveolitis associated with rheumatoid arthritis is better than cryptogenic fibrosing alveolitis. Rheumatology (Oxford). 2003;42(4):603-604; author reply 604-605.